Meropenem vaborbactam ema approval date?

What is the EMA approval date for meropenem–vaborbactam?

Meropenem–vaborbactam (Vaborem) received European Medicines Agency (EMA) approval on 28 April 2020. [1]

Where does that approval apply (which indication, and what is the product called in the EU)?

In the EU, the EMA approval is for Vaborem (meropenem–vaborbactam) for the treatment of certain complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI), including infections caused by carbapenem-susceptible and some carbapenem-resistant organisms as specified in the product’s approved label. [1]

What are the key document types to look for on EMA (and why the date can appear in more than one place)?

When users search “EMA approval date,” they may encounter multiple related timestamps on EMA pages:
- the date of the European Commission decision authorizing the medicine after EMA review, and
- the EMA product information pages that reflect the authorized wording and timing.
The commonly cited “EMA approval date” corresponds to the authorization outcome reflected in EMA’s public materials and is listed as 28 April 2020 for meropenem–vaborbactam. [1]

Sources:
[1] https://www.ema.europa.eu/en/medicines/human/EPAR/vaborem